Isoalantolactone induces intrinsic apoptosis through p53 signaling pathway in human lung squamous carcinoma cells

Chengyan Jin1, Guangxin Zhang1, Yifan Zhang1

  • 1Jilin Provincial Key Laboratory on Molecular and Chemical Genetic, The Second Hospital of Jilin University, Changchun, P.R. China.

Plos One
|August 5, 2017
PubMed

Insights

Isoalantolactone triggers apoptosis in human lung squamous carcinoma cells by activating p53. This natural compound shows potential as a novel anti-lung cancer therapeutic agent.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Isoalantolactone demonstrates apoptosis-inducing properties in various cancer types.
  • Limited research exists on its efficacy against human lung cancer.

Purpose of the Study:

  • To investigate the anti-tumor effects of Isoalantolactone on human lung squamous carcinoma SK-MES-1 cells.
  • To elucidate the underlying molecular mechanisms of its action.

Main Methods:

  • Cell viability assays to assess SK-MES-1 cell growth.
  • Apoptosis induction analysis, including DNA fragmentation and morphological changes.
  • Western blotting to examine key protein expressions (p53, Bcl-2, Bax, Caspase-3, PARP).
  • Mitochondrial membrane potential and reactive oxygen species (ROS) generation assays.
  • Cell cycle analysis.

Main Results:

  • Isoalantolactone significantly reduced SK-MES-1 cell viability in a dose-dependent manner.
  • The compound induced characteristic apoptotic morphological and DNA changes.
  • Isoalantolactone activated the p53 signaling pathway, leading to G1 phase cell cycle arrest.
  • Down-regulation of Bcl-2 and up-regulation of Bax were observed, alongside mitochondrial dysfunction and ROS generation.
  • Activation of Caspase-3 and cleavage of PARP confirmed apoptosis induction.

Conclusions:

  • Isoalantolactone effectively induces intrinsic apoptosis in human lung squamous carcinoma SK-MES-1 cells via the p53 signaling pathway.
  • These findings highlight Isoalantolactone as a promising candidate for developing new anti-lung cancer therapies.